JEHAN HELMI: Open Payments
NPI 1497986285 · FOLSOM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,378 in 73 payments from 11 companies in 2025. Trend: 2023 $53 · 2024 $112 · 2025 $1,378
Food & beverage: $1,378
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $426 |
| E.R. Squibb & Sons, L.L.C. | 16 | $240 |
| Teva Pharmaceuticals USA, Inc. | 7 | $209 |
| ABBVIE INC. | 11 | $180 |
| Alkermes, Inc. | 4 | $85 |
| Luye Pharma (USA) Ltd. | 3 | $69 |
| Neurocrine BioSciences, Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Indivior Inc. | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
Products named: COBENFY, REXULTI, AUSTEDO XR, VRAYLAR, ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
